REGULATION OF GENOME-SCALE CRISPR ACTIVATION SYSTEMS

1. INTRODUCTION

Genome-scale CRISPR activation (CRISPRa) is a biotechnology platform that increases the expression of selected genes without necessarily altering the underlying DNA sequence. It may support drug discovery, functional genomics, regenerative medicine and investigations into complex diseases. Genome-scale applications can influence numerous genes and biological pathways, creating challenges involving unintended effects, reproducibility, patient safety and ethical oversight.

In India, regulation depends on the intended application. Human therapeutic development may be governed by the Drugs and Cosmetics Act, 1940, the New Drugs and Clinical Trials Rules, 2019, and applicable gene-therapy guidelines. Research involving regulated genetically engineered organisms may fall under the Environment (Protection) Act, 1986, and the 1989 Biosafety Rules. The National Guidelines for Gene Therapy Product Development and Clinical Trials, 2019, provide an important framework for human gene-therapy research.

2. LEGAL AND REGULATORY FRAMEWORK

A. HUMAN THERAPEUTIC APPLICATIONS

Where CRISPRa is developed as a therapeutic product, sponsors must determine the applicable CDSCO authorisation pathway, clinical-trial requirements and ethical approvals. Safety assessment should address unintended gene activation, immune reactions, delivery-system toxicity and persistence of the intervention. Genome-scale applications require particular attention to effects across biological pathways.

B. BIOSAFETY AND CONTAINMENT

The 1989 Biosafety Rules establish oversight of specified genetically engineered organisms, cells and related activities. Institutional Biosafety Committees and the Review Committee on Genetic Manipulation perform relevant oversight functions. Whether a particular CRISPRa system falls within these requirements depends on the material, activity and applicable regulatory provisions.

C. ETHICAL AND DATA GOVERNANCE

Human research requires appropriate consent, ethics review and protection of personal information. Where CRISPRa involves human cells, researchers should document sample provenance, permitted uses and relevant privacy safeguards. Germline or heritable applications raise additional ethical and regulatory concerns and cannot be assumed permissible merely because the technique activates genes rather than cutting DNA.

3. PRINCIPAL REGULATORY REQUIREMENTS

First, researchers should characterise the system's mechanism, intended biological effects and potential unintended consequences. Second, sponsors should establish validated quality-control procedures, reproducibility standards and traceable experimental records. Third, human studies require appropriate authorisation, independent ethics review and informed consent. Fourth, researchers must comply with applicable containment, reporting and environmental-release restrictions. Finally, continued monitoring should identify adverse effects, unexpected gene-expression changes and other safety signals.

4. RELEVANT CASE LAWS

1. Gene Campaign v. Union of India, 2024 INSC 545 — DIRECT AUTHORITY ON GMO REGULATORY OVERSIGHT

The Supreme Court examined India's genetically modified crop regulatory framework and the role of judicial review in decisions involving genetically modified organisms. The judgment is relevant to the governance of CRISPRa where the system falls within applicable GMO regulation. It does not specifically decide the legality of genome-scale CRISPRa.

2. Vellore Citizens' Welfare Forum v. Union of India, (1996) 5 SCC 647 — ANALOGOUS AUTHORITY

The Supreme Court recognised the precautionary principle and polluter-pays principle as important features of Indian environmental law. These principles support preventive assessment where engineered biological systems could produce serious or irreversible environmental harm.

3. A.P. Pollution Control Board v. Prof. M.V. Nayudu, (1999) 2 SCC 718 — ANALOGOUS AUTHORITY

The Court emphasised the importance of scientific expertise in environmental decisions involving uncertainty. This reasoning supports independent scientific assessment of unintended gene activation, biological interactions and long-term safety concerns.

4. Justice K.S. Puttaswamy (Retd.) v. Union of India, (2017) 10 SCC 1 — ANALOGOUS CONSTITUTIONAL AUTHORITY

The Supreme Court recognised privacy as a fundamental right. Its principles are relevant when CRISPRa research uses identifiable genomic information, human biological samples or sensitive medical data.

5. Samira Kohli v. Dr. Prabha Manchanda, (2008) 2 SCC 1 — ANALOGOUS AUTHORITY

The Court established principles governing voluntary and informed medical consent. These principles support meaningful disclosure of foreseeable risks, alternatives and research procedures in clinical studies involving CRISPRa-based interventions.

6. Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013) — ANALOGOUS INTELLECTUAL-PROPERTY AUTHORITY

The United States Supreme Court distinguished naturally occurring DNA from certain synthetically created DNA for patent-eligibility purposes. Although it did not concern CRISPRa, the decision illustrates the legal distinction between biological discoveries and human-engineered innovations. It is persuasive comparative authority, not binding Indian law.

5. PRACTICAL COMPLIANCE

Institutions should maintain documented risk assessments, appropriate biosafety approvals, validated research procedures and auditable records. Sponsors should obtain applicable clinical-trial permissions before human testing, establish adverse-event reporting systems and monitor long-term effects where scientifically justified. Environmental applications require assessment under the relevant biosafety and release framework.

6. CONCLUSION

Genome-scale CRISPRa offers significant scientific and therapeutic potential, but its regulation must reflect the breadth of its biological effects. Indian drug, biosafety, ethical and privacy frameworks provide the principal legal safeguards. The cited judgments supply relevant principles concerning precaution, scientific scrutiny, autonomy and intellectual property; most are analogous rather than direct CRISPRa authorities. Effective oversight should enable responsible innovation while protecting human health, environmental safety and individual rights.